This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...
(COLORADO SPRINGS) — FOX21 News has learned alternative ways people are getting around the shortage of the medical device called the Dexcom, a glucose monitor for diabetes. Some diabetics are now ...
TipRanks on MSN
DEXCOM call volume above normal and directionally bullish
Bullish option flow detected in DexCom (DXCM) with 1,753 calls trading, 1.1x expected, and implied vol increasing almost 2 points to 45.27%.
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...
Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
Dexcom stands as the US leader in the continuous glucose monitoring (CGM) space as it continues to innovate and diversify its product lines to simplify blood glucose monitoring for type 2 diabetes ...
Apple Watches are more than just feature-packed wearables; they're important tools for monitoring our health, including our heart rate, sleep patterns, and cardio fitness. Even if you don't know every ...
In 2022, Dexcom began rolling out in Europe the Dexcom One system, a straightforward continuous glucose monitoring setup that stripped away some of the bells and whistles of its flagship G-series CGMs ...
Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the ...
DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback